NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root

Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes

(2019) Ralph A DeFronzo et al.   Diabetes & Vascular Disease Research

Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial

(2019) Anirudh Kumar et al.   Diabetes & Vascular Disease Research

The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis

(2019) Zobair M. Younossi et al.   JOURNAL OF HEPATOLOGY

Impaired skeletal muscle mitochondrial pyruvate uptake rewires glucose metabolism to drive whole-body leanness

(2019) Arpit Sharma et al.   eLife

PNPLA3 I148M and liver fat and fibrosis scores predict liver disease mortality in the United States population

(2019) Aynur Unalp‐Arida et al.   HEPATOLOGY

Classification of Type 2 Diabetes Genetic Variants and a Novel Genetic Risk Score Association with Insulin Clearance

(2019) Mark O Goodarzi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

(2019) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis

(2018) Jerry R. Colca et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)

(2018) Pegah Golabi et al.   MEDICINE

Insulin Action Research and the Future of Diabetes Treatment: The 2017 Banting Medal for Scientific Achievement Lecture

(2018) Domenico Accili   DIABETES

PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development

(2018) Steven P. Tanis et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis

(2017) Kyle S. McCommis et al.   HEPATOLOGY

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets

(2017) Yadan Chen et al.   PPAR Research

Basal hyperinsulinemia beyond a threshold predicts major adverse cardiac events at 1 year after coronary angiogram in type 2 diabetes mellitus: a retrospective cohort study

(2017) Mukund Srinivasan et al.   Diabetology & Metabolic Syndrome

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis

(2017) Giovanni Musso et al.   JAMA Internal Medicine

The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity

(2017) Adam J. Rauckhorst et al.   Molecular Metabolism

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes

(2016) Romina Lomonaco et al.   DIABETES CARE

The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health

(2016) Mary Rinella et al.   HEPATOLOGY

Mitochondrial pyruvate transport: a historical perspective and future research directions

(2015) Kyle S. McCommis et al.   BIOCHEMICAL JOURNAL

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD

(2015) Jessica Bazick et al.   DIABETES CARE

The TZD insulin sensitizer clue provides a new route into diabetes drug discovery

(2015) Jerry R. Colca   Expert Opinion on Drug Discovery

Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes

(2014) Raymond E. Soccio et al.   Cell Metabolism

Cardiovascular Health and Protection Against CVD

(2014) Donald M. Lloyd-Jones   CIRCULATION

Mitochondrial target of thiazolidinediones

(2014) J. R. Colca et al.   DIABETES OBESITY & METABOLISM

All-Cause and Cardiovascular Mortality in Middle-Aged People With Type 2 Diabetes Compared With People Without Diabetes in a Large U.K. Primary Care Database

(2013) K. S. Taylor et al.   DIABETES CARE

Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases

(2013) Jerry R Colca et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

(2013) Quentin M. Anstee et al.   Nature Reviews Gastroenterology & Hepatology

The global NAFLD epidemic

(2013) Rohit Loomba et al.   Nature Reviews Gastroenterology & Hepatology

Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins

(2013) Jerry R. Colca et al.   PLoS One

Insulin Resistance and Metabolic Derangements in Obese Mice Are Ameliorated by a Novel Peroxisome Proliferator-activated Receptor γ-sparing Thiazolidinedione

(2012) Zhouji Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

(2011) Silvia Sookoian et al.   HEPATOLOGY

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Genetic Architecture of Type 2 Diabetes: Recent Progress and Clinical Implications

(2009) R. W. Grant et al.   DIABETES CARE